Latest Breaking News On - Refractory multiple - Page 6 : comparemela.com

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

Hong kongUnited statesLugui qiuEli lillyInnovent biologicsChunrui liEquecabtagene autoleucelAdimab incyteIncyte corporationPrnewswire innovent biologics incHuazhong university of science technologyTongji medical collegeInternational myeloma societyChina national medical products administrationMd anderson cancer centerChinese academy of medical science hematology hospital

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United statesHong kongEli lillyAdimab incyteChunrui liLugui qiuEquecabtagene autoleucelIncyte corporationInnovent biologics incMd anderson cancer centerInternational myeloma societyTongji medical collegeChina national medical products administrationHuazhong university of science technologyChinese academy of medical science hematology hospitalComplete response

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody.

Lugui qiuAdimab incyteChunrui liEli lillyA equecabtagene autoleucelEquecabtagene autoleucelInnovent biologicsInnovent biologics incInternational myeloma societyHuazhong university of science technologyChinese academy of medical science hematology hospitalMd anderson cancer centerTongji medical collegeChina national medical products administrationComplete responseAbstract code

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

/PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that.

United statesUnited kingdomSouth koreaKyongsang buktoHong kongReshma rangwalaKaryopharm selective inhibitor of nuclear exportEuropean unionInternational myeloma societyInformation departmentKaryopharm therapeutics incSelective inhibitor of nuclear exportExchange commissionEuropean society of gynaecological oncologyDrug administrationKaryopharm therapeutics

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U S Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U S Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesWilliam caoMarvin tangJessica laubStephanie carringtonAmerican society for clinical oncologyGracell biotechnologies incExchange commissionFierce life sciences innovationEuropean hematology associationBiotechnologies doses first patientRefractory multipleChief executive officerAmerican societyClinical oncologyBiotech innovation